Double ‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study

Diabetes, Obesity and Metabolism,Volume 0, Issue ja, -Not available-.

Source: Diabetes, Obesity and Metabolism - November 5, 2018 Category: Endocrinology Authors: Ronan Roussel, Santiago Dur án García, Yilong Zhang, Suneri Shah, Carolyn Darmiento, R. Ravi Shankar, Gregory T. Golm, Raymond L.H. Lam, Edward A. O'Neill, Ira Gantz, Keith D. Kaufman, Samuel S. Engel Source Type: research